Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Cancers|April 3, 2021
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome ResistanceMoritz Fürstenau, Barbara Eichhorst
Haematologica|October 6, 2019
Sequential and combination treatments with novel agents in chronic lymphocytic leukemiaMoritz Fürstenau, Michael Hallek, Barbara Eichhorst
Hematology. American Society of Hematology. Education Program|December 7, 2019
Relapsed disease and aspects of undetectable MRD and treatment discontinuationBarbara Eichhorst, Moritz Fürstenau, Michael Hallek
Hemasphere|January 17, 2020
Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?Moritz Fürstenau, Nisha De Silva, Barbara Eichhorst, et al.
Leukemia Research|April 12, 2026
Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantationDaniel Schütte, Eva-Maria Call, Moritz Fürstenau, et al.
European Journal of Haematology|June 24, 2020
COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemiaPetra Langerbeins, Moritz Fürstenau, Henning Gruell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 24, 2012
Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trialArti Basra, Ghyslain Mombo-Ngoma, Meskure Capan Melser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Blood|June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutationsPaula Cramer, Eugen Tausch, Julia von Tresckow, et al.
Pageof 3